top of page
Executive Spotlights

Mirum Pharmaceuticals to Acquire Travere's Bile Acid Product Portfolio for $445M

Foster City, CA, July 17, 2023 (Business Wire) -- Mirum Pharmaceuticals and Travere Therapeutics have finalized a deal for the sale of Travere's bile acid product portfolio, including Cholbam® and Chenodal®, for patients with liver disease. The acquisition, valued at $445 million, strengthens Mirum's pipeline and reinforces its position in pediatric hepatology, while enabling Travere to focus on its pipeline of innovative medicines for rare diseases.

Read full article here.

Recent Posts

See All
Life Science Headlines
bottom of page